<DOC>
	<DOCNO>NCT01921205</DOCNO>
	<brief_summary>Study evaluate efficacy Lacosamide ( LCM ) administer addition 1 ≤3 Anti-Epileptic Drugs subject epilepsy ≥4 year &lt; 17 year age currently uncontrolled partial onset seizure .</brief_summary>
	<brief_title>Study Investigate Lacosamide Add-on Therapy Subjects ≥4 Years &lt; 17 Years Age With Partial Onset Seizures</brief_title>
	<detailed_description>The primary objective study evaluate efficacy LCM administer concomitantly 1 ≤3 Anti-Epileptic Drugs ( AEDs ) subject epilepsy ≥4 year &lt; 17 year age currently uncontrolled partial onset seizure . The secondary objective evaluate safety tolerability LCM subject ≥4 year &lt; 17 year age . An additional objective evaluate pharmacokinetics ( PK ) LCM subject ≥4 year &lt; 17 year age .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<criteria>An Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve write Informed Consent form sign dated parent ( ) legal representative . The Informed Consent form specific Assent form , require , sign dated minor Subject/legal representative consider reliable capable adhere protocol ( eg , able understand complete diary ) , visit schedule , medication intake accord judgment investigator Subject male female ≥4 year &lt; 17 year age Subject diagnosis Epilepsy partialonset seizure . The result ≥1 prior electroencephalogram ( EEG ) AND 1 prior magnetic resonance imaging/computerized tomography scan consistent diagnosis Subject observe uncontrolled partialonset seizure adequate course treatment ( opinion investigator ) ≥2 AntiEpileptic Drugs ( AEDs ) ( concurrently sequentially ) Subject must observe average ≥2 partial onset seizure per 28 day seizure free phase longer 21 day 8 week period prior entry Baseline Period . During study , subject must report ≥2 partial onset seizure 8 week prospective Baseline Period eligible randomization Visit 2 . ( Note : In case simple partial onset seizure , seizure motor sign count towards meet inclusion criterion . ) Subject stable dosage regimen 1 ≤3 AEDs . The daily dosage regimen concomitant AED therapy must keep constant period ≥4 week prior Baseline Period Vagal nerve stimulation ( VNS ) allow count concomitant AED . The VNS device must implant ≥6 month Visit 1 , device setting must stable ≥4 week Visit 1 keep stable Baseline Period . Use VNS device magnet allow Subject previously participate study subject assign Lacosamide ( LCM ) previous LCM study Subject participate another study investigational medicinal product ( IMP ) medical device within ≤2 month Visit 1 currently participate another study IMP medical device Subject medical psychiatric condition , opinion investigator , could jeopardize would compromise subject 's ability participate study Subject ≥6 year age lifetime history suicide attempt ( include actual attempt , interrupt attempt , aborted attempt ) , suicidal ideation past 6 month indicate positive response ( `` Yes '' ) either Question 4 Question 5 Columbia Suicide Severity Rating Scale ( C SSRS ) Screening Subject know hypersensitivity component IMP ever receive LCM Female subject pregnant nursing , and/or female subject childbearing potential surgically sterile practice 1 highly effective method contraception ( accord International Conference Harmonisation [ ICH ] guidance define result failure rate le 1 % per year use consistently correctly ) , unless sexually abstinent , duration study . Female subject childbearing potential take enzyme induce antiepileptic drug ( EI AEDs : carbamazepine , phenytoin , barbiturate , primidone , topiramate , oxcarbazepine ) surgically sterile practice 1 highly effective method contraception accord WHO recommendation ( ie , depot medroxyprogesterone acetate , norethisterone enantate , intrauterine device , combine injectables , progestogen implant ) administration EI AEDs OR practice 2 combine method contraception ( ie , combine hormonal contraception plus barrier method spermicidal agent ) , unless sexually abstinent , duration study Subject medical condition could expect opinion investigator interfere drug absorption , distribution , metabolism , excretion Subject experience febrile seizure exclusively . The occurrence febrile seizures addition unprovoked seizure exclusionary Subject ketogenic specialize diet . If subject specialize diet past , must diet ≥2 month prior Baseline Period Subject alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin level ≥2 time upper limit normal ( ULN ) , creatinine clearance le 30 mL/min Subject clinically relevant ECG abnormality , opinion investigator ( eg , second third degree heart block rest correct QT interval [ QTc ] great 450 m ) Subject hemodynamically significant congenital heart disease Subject arrhythmic heart condition require medical therapy Subject know history severe anaphylactic reaction serious blood dyscrasia Subject nonepileptic event could confuse seizure Subject current diagnosis LennoxGastaut syndrome , primary generalize epilepsy , mixed seizure disorder ( partial primarily generalize seizure ) , purely nocturnal seizure Subject history convulsive status epilepticus ≤2 month prior Baseline Period Subject treat vigabatrin experienced vision loss . Subjects receive vigabatrin past must documentation assessment vision loss prior study entry documentation visual field test perform Subject treat felbamate experience serious toxicity issue ( define liver failure , aplastic anemia ) treatment . Subjects treat felbamate &lt; 12 month exclude . Note : subject treat felbamate ≥12 month experience serious toxicity issue eligible Subject medically document history alcohol drug abuse Subject know cardiac sodium channelopathy , Brugada syndrome Subject acute sub acutely progressive central nervous system disease . Subject epilepsy secondary progress cerebral disease progressively neurodegenerative disease ( malignant brain tumor Rasmussen Syndrome )</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat</keyword>
	<keyword>UCB</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>Pediatric</keyword>
</DOC>